It’s a safety trial mainly, but they tested a bunch of efficacy endpoints as well- mostly various measures of speech understanding in noise. The drug addresses the fairly recently described condition of synaptopathy. It’s not supposed to move thresholds, but improve understanding.
small numbers, no change in the placebo group, a number of participants who received the highest dosage showed ‘meaningful clinical improvement’.
It’s interesting to me as a proof of concept. It would be nice to see the full results.